STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a decline in total revenue and gross profit, increased operating expenses, and significant cash usage in operations, leading to liquidity concerns. The Q&A section highlights uncertainties around international business due to potential tariffs and ongoing legal issues. Management's reluctance to provide specific guidance further adds to the negative sentiment. Despite the positive impact of the Elevate 360 model, the overall outlook remains negative due to these challenges.
Key Financial Performance
Total Revenue $7.7 million, down 9% compared to Q2 of 2024. This decline was primarily driven by the challenging international environment.
Global Recurring Revenue $5.1 million, down 4% versus the prior year period.
XTRAC Gross Domestic Recurring Billings $4.7 million, a decline of 2% versus the prior year period.
Equipment Business Revenue $2.5 million, down 18% versus the second quarter of 2024. This was due primarily to challenges in specific international markets with lingering trade disputations in China and supplier challenges in Korea.
Gross Profit $4.3 million or 56% of revenue, declined from $5 million during the same period in 2024. The reduction in gross profit was driven primarily by lower sales with increases in manufacturing overhead contributing.
Total Operating Expenses $6.5 million, up roughly $1 million versus $5.5 million in the prior year period. Selling and marketing increased 16% due to increases in headcount in the sales and call center and increase in DTC spending. G&A expense increased roughly $700,000, with $340,000 due to litigation expenses.
Adjusted EBITDA Loss of $762,000.
Cash Used in Operations $1.9 million in the second quarter. Of this, $1.3 million represents a payment of restricted cash to the state of New York related to the sales tax accrual from Q3 2024. The remaining $600,000 includes $340,000 related to legal expenses.
Cash and Equivalents $6 million as of June 30, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
XTRAC 308-nanometer excimer laser: Expanded CPT codes to include multiple inflammatory and autoimmune skin conditions beyond psoriasis, effective January 1, 2027. Temporary G codes may accelerate access to 2026, potentially tripling the addressable market to 30 million patients.
TheraClearX: Installed base increased to 161 devices in the U.S. by Q2 2025, up from 117 in Q2 2024. Represents a growing portion of revenue.
Domestic Market Expansion: Direct-to-consumer (DTC) campaigns and Elevate 360 consulting model are driving increased utilization of XTRAC devices. Generated 1,100 DTC-driven patient appointments in Q2 2025 with a 61% show rate.
International Market Challenges: International revenue declined 15% YoY to $2.6 million in Q2 2025 due to trade disruptions in China and distributor issues in Korea. Strong demand expected to return once conditions stabilize.
Device Optimization: Removed 21 XTRAC devices from suboptimal partners and placed 19 with new accounts in Q2 2025, marking the highest U.S. placements in six quarters.
Recurring Revenue: Global recurring revenue was $5.1 million in Q2 2025, down 4% YoY. Domestic recurring billings for XTRAC declined 2% YoY to $4.7 million.
Litigation Against LaserOptek: Legal action for false and misleading marketing statements. Court added LaserOptek Korea and C. Dalton, LLC as defendants, potentially leading to significant damages.
Combination Therapy Expansion: Peer-reviewed studies support the use of XTRAC with JAK inhibitors for vitiligo and atopic dermatitis, opening new market opportunities. STRATA owns patents for these combination treatments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs and Trade Disruptions: Uncertainty about tariffs and trade disruptions, particularly in China, has created a temporary drag on international business, with international revenue declining 15% compared to the prior year period. Lingering trade disruptions in China and distributor challenges in Korea have significantly affected international equipment sales.
Seasonality and Revenue Fluctuations: The company experiences seasonality in its business, with slower first and second quarters. This seasonality could impact revenue predictability and financial performance.
Litigation Costs: Legal expenses related to litigation against LaserOptek have increased G&A expenses by approximately $340,000 in the second quarter, contributing to overall financial strain.
Decline in Revenue and Gross Profit: Total revenue for Q2 2025 declined by 9% compared to Q2 2024, driven by challenges in international markets. Gross profit also declined from $5 million to $4.3 million, primarily due to lower sales and increased manufacturing overhead.
Device Placement Optimization: The company removed 21 devices from suboptimal partners and placed 19 devices with new accounts. While this represents progress, the net reduction in devices placed could impact short-term revenue.
Cash Flow and Operational Costs: Cash used in operations was $1.9 million in Q2 2025, with significant portions allocated to legal expenses and a payment related to a sales tax accrual. This could strain liquidity.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Opportunities: The company expects to accelerate access to revised CPT codes through temporary G codes, potentially pulling forward revenue opportunities by one year into 2026. This is due to expanded reimbursement eligibility for excimer laser treatments for multiple inflammatory and autoimmune skin conditions.
Market Expansion: The addressable market is expected to expand to 30 million patients, tripling the total available market (TAM). This expansion is driven by the inclusion of new indications for excimer laser treatments.
Reimbursement Rates: The company has submitted economic data to support a potential increase in reimbursement rates for its codes, which could lead to simultaneous growth in the number of eligible patients and revenue per patient procedure.
Device Utilization: The company anticipates significant opportunities to increase utilization of its XTRAC devices, supported by expanded CPT codes and direct-to-consumer marketing campaigns.
International Business: The company expects international markets, particularly China and Korea, to return to growth once trade disruptions and distributor challenges stabilize.
Seasonality: The company anticipates a seasonally stronger second half of 2025, with positive momentum heading into year-end.
Combination Therapy Market: The company is preparing for market expansion into combination therapy for challenging patients, supported by recent patents and clinical studies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us a sense of what your back half of the year expectation is as far as the international business?
A:The expectation for the second half of the year is to be similar to last year. However, this is uncertain due to potential tariff changes, particularly in China. The management refrained from providing specific guidance but noted that international revenue could be significantly impacted by tariffs.
Q:Can you give us a sense of cost for the back half of the year and where you're at with the lawsuit involving the three entities?
A:The lawsuit involves LaserOptek's false advertising and misleading claims about their devices. STRATA has incurred significant damages in the 8-digit range due to lost accounts and market confusion. Most legal expenses are behind, and the case is in the discovery phase. The inclusion of two new defendants may extend the case, but STRATA is confident in recouping damages.
Q:Could you give us a sense of how many units during this period were placed out there in the marketplace by LaserOptek?
A:The exact number of units placed by LaserOptek is unknown as this information was hidden. STRATA has estimates and knows some accounts but lacks precise data due to LaserOptek's legal practices.
Q:Is there anything else on your end that has to be done regarding the temporary G codes? What time frame could we expect a response?
A:The review process for temporary G codes is ongoing. CMS is reviewing data and comments, with a final rule expected in November. STRATA has provided extensive data to support their case, including device utilization and reimbursement adjustments.
Q:Are there any metrics you could share on how the Elevate 360 consulting services have impacted clinics?
A:While specific metrics were not prepared for this call, clinics that completed the Elevate 360 process showed higher revenue in Q2 compared to the previous year. STRATA plans to share detailed metrics in future disclosures.
Q:Are you going through the same review process for the TheraClear devices as you are for the XTRAC installed base?
A:The main focus is on XTRAC devices due to their higher revenue potential. TheraClear's installed base is growing but at a slower pace. STRATA expects to reach 200 TheraClear devices by the end of 2025 and has shifted focus to clinics billing codes rather than cash-pay patients.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the international business and the number of units placed by LaserOptek, citing uncertainty and lack of data. Additionally, metrics for the Elevate 360 consulting services were not disclosed during this call.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CPT code
GA expense
LLC
LaserOptek Korea
Research Division
STRATA Skin
Skin Sciences
VASI improvement
access
addition
challenge Korea
code reimbursement
damage
defendant
dermatitis
development
eligibility
excimer laser
expansion
laser inhibitor
laser therapy
litigation LaserOptek
marketing
nanometer excimer
repigmentation study
response
revision
seasonality
trial
vitiligo
week
SSKN Transcript
STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript
Unknown11-13
Despite some positive aspects like increased recurring revenue and improved operating expenses, the overall sentiment is negative due to a significant decline in total and equipment revenue, persistent international challenges, and unclear guidance on key metrics like DTC campaign impact. The Q&A revealed management's avoidance of direct answers, which adds uncertainty. The lack of temporary CPT codes for 2026 and tariff impacts further contribute to a negative outlook. The absence of a market cap suggests a potentially stronger reaction, leaning towards a negative stock price movement.
STRATA Skin Sciences, Inc. (SSKN) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary indicates a decline in total revenue and gross profit, increased operating expenses, and significant cash usage in operations, leading to liquidity concerns. The Q&A section highlights uncertainties around international business due to potential tariffs and ongoing legal issues. Management's reluctance to provide specific guidance further adds to the negative sentiment. Despite the positive impact of the Elevate 360 model, the overall outlook remains negative due to these challenges.
Earnings call transcript: STRATA Skin Sciences sees modest growth in Q1 2025
Unknown5-14
The earnings call summary presents a mixed picture. Financial performance shows modest growth with improved margins and reduced expenses, but concerns about tariffs and competitive pressures weigh negatively. The Q&A section highlights management's unclear responses about tariffs, adding uncertainty. While international sales growth is a positive, the overall sentiment remains cautious due to flat growth in the installed base and operational challenges. Given the absence of strong catalysts or negative surprises, a neutral stock price movement is predicted.
STRATA Skin Sciences, Inc. (SSKN) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call summary presents mixed signals. While there are improvements in gross margin, cash flow, and certain revenues, overall revenue growth is minimal. The Q&A reveals concerns about tariffs and unclear management responses, impacting sentiment negatively. The positive factors such as improved cash burn and gross margin are offset by competitive pressures and regulatory issues. Given these mixed results and uncertainties, the stock price reaction is likely to be neutral in the absence of significant catalysts.
SSKN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
